Temoporfin

Temoporfin
Systematic (IUPAC) name
	3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
Clinical data
AHFS/Drugs.com	International Drug Names
Licence data	EMA:Link
Legal status	℞ (Prescription only);
Identifiers
CAS Number	122341-38-2
ATC code	L01XD05 (WHO)
PubChem	CID: 60751
ChemSpider	54754
UNII	FU21S769PF
KEGG	D06066
ChEMBL	CHEMBL383675
Chemical data
Formula	C44H32N4O4
Molecular mass	680.74 g/mol
	SMILES c1cc(cc(c1)O)c2/c3ccc([nH]3)/c(c/4\nc(/c(c\5/cc/c(/[nH]5)c(/c6n\c2\CC6)\c7cccc(c7)O)/c8cccc(c8)O)C=C4)/c9cccc(c9)O ;
	InChI InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40- ; Key:LYPFDBRUNKHDGX-LWQDQPMZSA-N ;
(verify)

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck^[1] .^[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.^[3]

Good results were obtained in 21 of 35 patients treated in Germany.^[4]

It is photoactivated at 652 nm^[5] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ ^2.0 ^2.1 Lua error in package.lua at line 80: module 'strict' not found.
↑ http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
↑ http://www.springerlink.com/content/g74w224824v8l013/
↑ Lua error in package.lua at line 80: module 'strict' not found.